eiden Thrombosis Recurrence Risk Prevention: Tailored treatment after a first venous thromboembolism: (L-TRRiP study)
- Conditions
- 'Venous thromboembolism' 'thrombosis'10014523
- Registration Number
- NL-OMON54327
- Lead Sponsor
- eids Universitair Medisch Centrum
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- Not specified
- Target Recruitment
- 1600
1. Provision of informed consent prior to any study specific procedures.
2. Be diagnosed with a first confirmed symptomatic deep vein thrombosis
(including distal vein thrombosis, in Dutch ' kuitvenetrombose') or pulmonary
embolism with an indication for treatment with anticoagulant therapy for at
least 3 months as prescribed by their treating physician.
3. Be aged 18 years or above.
1. Patients with active cancer (i.e. cancer diagnosis within six months before
VTE (excluding basal-cell or squamous-cell carcinoma of the skin), recently
recurrent or progressive cancer or any cancer that required anti-cancer
treatment within six months before the venous thromboembolism was diagnosed) or
antiphospholipid syndrome
2. Patients who need to continue anticoagulant treatment for another indication
(e.g. atrial fibrillation).
3. Patients with a strong indication for long-term antiplatelet therapy despite
oral anticoagulation (e.g. those with recent STEMI)
4. Patients with COVID-19 associated VTE (i.e. hospital admission because of
COVID-19 <3 months before VTE) or vaccine-induced immune thrombotic
thrombocytopenia (VITT)
5. Patients in whom the risk of bleeding is deemed extremely high by the
treating physician, necessitating discontinuation of anticoagulant treatment
for the first VTE after the initial 3 months or even during the initial 3
months.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method